medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2012, Number 07-08

<< Back Next >>

Medicina & Laboratorio 2012; 18 (07-08)

Correlation among vaccination and the presence of protector antibodies anti-hepatitis B virus in the personnel of Universidad Cooperativa de Colombia Medical School-Medellín, 2011

Álvarez FCM, Ossa GAC, Pérez GLM, Cardona AJA

Language: Spanish
References: 26
Page: 355-363
PDF size: 221.36 Kb.


ABSTRACT

Introduction: health personnel is one of the main risk groups for infection with Hepatitis B virus, and although there is a vaccine based on recombinant surface antigen of the virus, not all vaccinated individuals reach protective antibody titers. Objective: to establish the relationship between serum titers of anti-Hepatitis B Virus and the number of doses of vaccine against hepatitis B, in staff of the Medical School at Universidad Cooperativa de Colombia, Medellin, in 2011. Materials and methods: a cross-sectional study in a probability sample of 162 people was conducted. The data collection was from primary source. Statistical analysis was made based on proportions, summary measures, parametric and nonparametric statistics. Results: 80% of the study group had protective antibodies, the average antibody titer was 396 mIU/mL, it was statistically associated with the number of doses, and there was no statistical association with sex or age. Conclusion: the protection found against hepatitis B virus was lower than that reported internationally for recombinant vaccines (approximately 90-95% in young adults). This could be attributed to the inclusion of people with incomplete vaccination schedules or poor immune response to the vaccine, such as men, individuals with high body mass index, adulthood, smoking status, and individuals with HLA DR3-DQ2.


REFERENCES

  1. World Health Organization. Hepatitis B fact sheet Nº 204 (revised 2008). http://www.who.int/mediacentre/ factsheets/fs204/en/index.html. 2012. Consultado en julio de 2012.

  2. Han YF, Zhao J, Ma LY, Yin JH, Chang WJ, Zhang HW, et al. Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma. World J Gastroenterol 2011; 17: 4258-4270.

  3. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005; 34 Suppl 1: S1-3.

  4. Organization WH. Hepatitis B vaccines. WHO position paper. Weekly epidemilogical record 2009; 84: 405-420.

  5. Echevarria JM, Leon P. Epidemiology of viruses causing chronic hepatitis among populations from the Amazon Basin and related ecosystems. Cad Saude Publica 2003; 19: 1583-1591.

  6. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006; 28: 112-125.

  7. República de Colombia, Ministerio de la Protección Sociail, Instituto Nacional de Salud. Protocolo de vigilancia y control de la Hepatitis B. 2011. http://190.26.202.205/index.php?idcategoria=38902# Consultado en julio de 2012.

  8. Dirección Seccional de Salud de Antioquia. Informe estadísticas de eventos de salud pública: enfermedades inmunoprevenibles por municipio 2000 – 2010. Medellín. http://www.dssa.gov.co/index.php/estadisticas/ eventos-de-salud-publica. Consultado en julio de 2012.

  9. Ramírez CA, Fernández DG, Valderrama SL, Gómez CH, Támara JR, Álvarez CA. Vacunación para hepatitis B en pacientes adultos infectados con virus de inmunodeficiencia humana. Rev Chil Infectol 2009; 26: 26-33.

  10. República de Colombia, Ministerio de la Protección Sociail, Instituto Nacional de Salud. Grupo Transmisibles, Subdirección de Vigilancia y Control en Salud Pública. Comportamiento epidemiológico de la hepatitis B, Colombia, 2005. Inf Quinc Epidem Nac 2006;11: 33-44.

  11. República de Colombia Ministerio de la Protección Social, Instituto Nacional de Salud. Hepatitis B. Inf Quinc Epidemiol Nac 2006;11: 297-312.

  12. Zamani F, Fallahian F, Hashemi F, Shamsaei Z, Alavian SM. Immune response to hepatitis B vaccine in health-care workers. Saudi J Kidney Dis Transpl 2011; 22: 179-184.

  13. Hincapié A, Domínguez MC, Garcés CP. Conocimientos y presencia de hepatitis B en los estudiantes de pregrado de la facultad de odontología de la Universidad de Antioquia en el año 2003. Rev Fac Odontol Univ Antioq 2004; 15: 28-38.

  14. Alter MJ, Margolis HS. The emergence of hepatitis B as a sexually transmitted disease. Med Clin North Am 1990; 74: 1529-1541.

  15. Navas M,C, Restrepo JC. Virus de las hepatitis. En: Díaz FJ, Estrada S, Franco L, Jaramillo JM, Maestre AE, Ospina S, et. al, editores. Microbiología de las enfermedades infecciosas. Medellín: Corporación para Investigaciones Biológicas (CIB). 2008.

  16. Zunino E. Epidemiología de la hepatitis B en Chile y esquemas de vacunación en Latinoamérica. Rev Chil Infectol 2002; 19: 140-155.

  17. Braeckman T, Van Herck K, Jilg W, Bauer T, Van Damme P. Two decades of hepatitis B vaccination in mentally retarded patients: effectiveness, antibody persistence and duration of immune memory. Vaccine 2012; 30: 4757-4761.

  18. de la Hoz F, Perez L, de Neira M, Hall AJ. Eight years of hepatitis B vaccination in Colombia with a recombinant vaccine: factors influencing hepatitis B virus infection and effectiveness. Int J Infect Dis 2008; 12: 183-189.

  19. Alves AS, Nascimento CM, Granato CH, Sato HK, Morgato MF, Pannuti CS. Hepatitis B vaccine in infants: a randomized controlled trial comparing gluteal versus anterolateral thigh muscle administration. Rev Inst Med Trop Sao Paulo 2001; 43: 139-143.

  20. Fessard C, Riche O, Cohen JH. Intramuscular versus subcutaneous injection for hepatitis B vaccine. Vaccine 1988; 6: 469.

  21. García P, De la Cerda G, Calvo M, Godoy R, Covarrubias C, Potin M, et al. Inmunogenicidad de una vacuna recombinante anti hepatitis B en personal de salud. Rev Chil Infectol 2002; 19: 133-139.

  22. Hollinger FB. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med 1989; 87: 36S-40S.

  23. Wood RC, MacDonald KL, White KE, Hedberg CW, Hanson M, Osterholm MT. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 1993; 270: 2935-2939.

  24. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998; 15: 1-8.

  25. Abbas AK, Litchman AH, Pillai S. Inmunología celular y molecular. Barcelona: Elsevier España; 2008.

  26. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55: 1-33; quiz CE31-34.




2020     |     www.medigraphic.com